Plasma-derived C1-inhibitor was the first-line treatment for life-threatening attacks in AAE, although some patients become refractory due to neutralizing autoantibodies, in which case agents such as ecallantide or icatibant – proven effective in HAE – may offer a rational and favorable alternative [9]. This evidence concerns the gene SERPING1 and hereditary angioedema.